Popular Articles

Chicago Team Uses Artificial Intelligence To Diagnose Metastatic Cancer
When doctors are managing care for women with breast cancer, the information available to them profoundly influences the type of care they recommend. Knowing whether a woman"s cancer has metastasized, for instance, directly affects how her doctors will approach treatment -- which may in turn influence the outcome of that treatment.
generic viagra online
Sosei And Vectura Announce Start Of Phase III Clinical Study With NVA237
Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. The study has now appeared on clinicaltrials.gov and will be recruiting in the next few weeks when the first patient first visit will trigger a $7.5 million milestone payment to both Sosei and Vectura.
News of the day
Lobbying Draws On Ranks Of Former Government Officials, Health Industry Coffers
"The nation"s largest insurers, hospitals and medical groups have hired more than 350 former government staff members and retired members of Congress in hopes of influencing their old bosses and colleagues, according to an analysis of lobbying disclosures and other records," the Washington Post reports. The Post"s analysis of lobbying disclosure records shows that three-quarters of major health firms have hired an insider to lobby on their behalf; half of those insiders once worked for the key senators and congressional committees that are now shaping the reform proposals.
Mental Health

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease

is insufficient to support regulatory approval; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials and studies may not be predictive of future results. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Amicus Therapeutics

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):